Non-small cell lung cancer nonsquamous · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin, Pemetrexed, Durvalumab N/A - protocol | — | R 277 964 | 28d | — | — | ~12 | ~R 2 165 465 indirect | — |
Cisplatin, Pemetrexed, Durvalumab N/A - protocol | — | R 277 068 | 28d | — | — | ~12 | ~R 2 161 879 indirect | — |
Cisplatin, Pemetrexed, Pembrolizumab Variant #01 | — | R 95 653 | 21d | — | — | 35 | R 2 924 218 PFS proxy | 1 |
Carboplatin and Pemetrexed Variant #01 | — | R 14 563 | 21d | ~5.1 mo | ~14.9 mo | ~10 | ~R 140 276 PFS proxy · indirect | 18 |
Cisplatin and Pemetrexed Variant #01 | — | R 13 666 | 21d | — | — | 7 | R 94 340 PFS proxy | 2 |
Cisplatin, Pemetrexed, Nivolumab Variant #01 Partial | — | R 13 666 | 21d | — | — | 13 | R 54 665 PFS proxy | 1 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | ~6.1 mo | ~14.2 mo | ~9 | ~R 9 222 PFS proxy · indirect | 7 |
7 of 7 regimens shown